vs
Side-by-side financial comparison of PLAYSTUDIOS, Inc. (MYPS) and ARS Pharmaceuticals, Inc. (SPRY). Click either name above to swap in a different company.
PLAYSTUDIOS, Inc. is the larger business by last-quarter revenue ($55.4M vs $28.1M, roughly 2.0× ARS Pharmaceuticals, Inc.). PLAYSTUDIOS, Inc. runs the higher net margin — -24.7% vs -147.1%, a 122.4% gap on every dollar of revenue. On growth, PLAYSTUDIOS, Inc. posted the faster year-over-year revenue change (-18.3% vs -67.6%).
PLAYSTUDIOS, Inc. develops and publishes free-to-play social and casual casino games for mobile, desktop and social platforms. It operates a loyalty rewards program that lets players redeem in-game achievements for real-world benefits including travel, dining and event tickets, serving markets across North America, Europe and Asia Pacific.
ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.
MYPS vs SPRY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $55.4M | $28.1M |
| Net Profit | $-13.7M | $-41.3M |
| Gross Margin | — | — |
| Operating Margin | -17.7% | -147.6% |
| Net Margin | -24.7% | -147.1% |
| Revenue YoY | -18.3% | -67.6% |
| Net Profit YoY | 38.9% | -182.8% |
| EPS (diluted) | $-0.12 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $55.4M | $28.1M | ||
| Q3 25 | $57.6M | $32.5M | ||
| Q2 25 | $59.3M | $15.7M | ||
| Q1 25 | $62.7M | $8.0M | ||
| Q4 24 | $67.8M | $86.6M | ||
| Q3 24 | $71.2M | $2.1M | ||
| Q2 24 | $72.6M | $500.0K | ||
| Q1 24 | $77.8M | $0 |
| Q4 25 | $-13.7M | $-41.3M | ||
| Q3 25 | $-9.1M | $-51.2M | ||
| Q2 25 | $-2.9M | $-44.9M | ||
| Q1 25 | $-2.9M | $-33.9M | ||
| Q4 24 | $-22.4M | $49.9M | ||
| Q3 24 | $-3.1M | $-19.1M | ||
| Q2 24 | $-2.6M | $-12.5M | ||
| Q1 24 | $-567.0K | $-10.3M |
| Q4 25 | -17.7% | -147.6% | ||
| Q3 25 | -13.6% | -163.7% | ||
| Q2 25 | -5.9% | -302.9% | ||
| Q1 25 | -4.4% | -466.3% | ||
| Q4 24 | -33.1% | 54.5% | ||
| Q3 24 | -6.7% | -1051.6% | ||
| Q2 24 | -5.5% | -3068.0% | ||
| Q1 24 | -2.2% | — |
| Q4 25 | -24.7% | -147.1% | ||
| Q3 25 | -15.8% | -157.4% | ||
| Q2 25 | -5.0% | -285.6% | ||
| Q1 25 | -4.6% | -425.7% | ||
| Q4 24 | -33.1% | 57.7% | ||
| Q3 24 | -4.3% | -925.0% | ||
| Q2 24 | -3.6% | -2503.2% | ||
| Q1 24 | -0.7% | — |
| Q4 25 | $-0.12 | $-0.41 | ||
| Q3 25 | $-0.07 | $-0.52 | ||
| Q2 25 | $-0.02 | $-0.46 | ||
| Q1 25 | $-0.02 | $-0.35 | ||
| Q4 24 | $-0.18 | $0.52 | ||
| Q3 24 | $-0.02 | $-0.20 | ||
| Q2 24 | $-0.02 | $-0.13 | ||
| Q1 24 | $0.00 | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $104.9M | $245.0M |
| Total DebtLower is stronger | — | $96.4M |
| Stockholders' EquityBook value | $227.9M | $114.3M |
| Total Assets | $290.6M | $327.7M |
| Debt / EquityLower = less leverage | — | 0.84× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $104.9M | $245.0M | ||
| Q3 25 | $106.3M | $288.2M | ||
| Q2 25 | $112.9M | $240.1M | ||
| Q1 25 | $107.1M | $275.7M | ||
| Q4 24 | $109.2M | $314.0M | ||
| Q3 24 | $105.2M | $204.6M | ||
| Q2 24 | $106.3M | $218.7M | ||
| Q1 24 | $127.0M | $223.6M |
| Q4 25 | — | $96.4M | ||
| Q3 25 | — | $96.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $227.9M | $114.3M | ||
| Q3 25 | $238.9M | $147.7M | ||
| Q2 25 | $245.3M | $192.3M | ||
| Q1 25 | $244.1M | $229.0M | ||
| Q4 24 | $244.7M | $256.8M | ||
| Q3 24 | $265.2M | $201.0M | ||
| Q2 24 | $263.6M | $215.2M | ||
| Q1 24 | $288.4M | $223.9M |
| Q4 25 | $290.6M | $327.7M | ||
| Q3 25 | $299.2M | $372.8M | ||
| Q2 25 | $316.2M | $313.5M | ||
| Q1 25 | $313.8M | $327.3M | ||
| Q4 24 | $323.0M | $351.2M | ||
| Q3 24 | $330.6M | $217.6M | ||
| Q2 24 | $333.4M | $222.0M | ||
| Q1 24 | $357.5M | $227.6M |
| Q4 25 | — | 0.84× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.7M | $-43.5M |
| Free Cash FlowOCF − Capex | $3.6M | — |
| FCF MarginFCF / Revenue | 6.5% | — |
| Capex IntensityCapex / Revenue | 0.2% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $25.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.7M | $-43.5M | ||
| Q3 25 | $5.7M | $-47.0M | ||
| Q2 25 | $13.6M | $-39.6M | ||
| Q1 25 | $3.3M | $-40.7M | ||
| Q4 24 | $11.6M | $42.0M | ||
| Q3 24 | $14.6M | $-14.5M | ||
| Q2 24 | $14.5M | $-7.3M | ||
| Q1 24 | $5.0M | $-6.7M |
| Q4 25 | $3.6M | — | ||
| Q3 25 | $5.4M | $-47.2M | ||
| Q2 25 | $13.2M | $-39.6M | ||
| Q1 25 | $3.2M | $-40.8M | ||
| Q4 24 | $11.5M | $41.7M | ||
| Q3 24 | $13.9M | $-14.6M | ||
| Q2 24 | $12.8M | $-7.3M | ||
| Q1 24 | $3.6M | $-6.8M |
| Q4 25 | 6.5% | — | ||
| Q3 25 | 9.3% | -145.4% | ||
| Q2 25 | 22.3% | -252.2% | ||
| Q1 25 | 5.1% | -512.1% | ||
| Q4 24 | 16.9% | 48.2% | ||
| Q3 24 | 19.6% | -706.3% | ||
| Q2 24 | 17.6% | -1463.4% | ||
| Q1 24 | 4.6% | — |
| Q4 25 | 0.2% | 0.0% | ||
| Q3 25 | 0.5% | 0.6% | ||
| Q2 25 | 0.7% | 0.3% | ||
| Q1 25 | 0.2% | 1.1% | ||
| Q4 24 | 0.2% | 0.3% | ||
| Q3 24 | 0.9% | 6.8% | ||
| Q2 24 | 2.4% | 7.6% | ||
| Q1 24 | 1.9% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.84× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MYPS
Segment breakdown not available.
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
